KP Tissue Inc. (TSE:KPT - Free Report) - Investment analysts at Desjardins lowered their Q4 2024 earnings per share (EPS) estimates for KP Tissue in a note issued to investors on Wednesday, November 13th. Desjardins analyst F. Tremblay now expects that the company will post earnings of $0.18 per share for the quarter, down from their previous estimate of $0.19. The consensus estimate for KP Tissue's current full-year earnings is $0.44 per share. Desjardins also issued estimates for KP Tissue's FY2025 earnings at $0.72 EPS.
Separately, TD Securities upped their price objective on KP Tissue from C$8.50 to C$9.00 and gave the company a "hold" rating in a research report on Wednesday, August 14th.
Get Our Latest Research Report on KP Tissue
KP Tissue Price Performance
KPT stock traded down C$0.03 during trading on Monday, hitting C$8.27. 12,606 shares of the stock traded hands, compared to its average volume of 18,947. The stock has a market cap of C$82.45 million, a price-to-earnings ratio of 13.83, a price-to-earnings-growth ratio of -0.88 and a beta of 0.37. KP Tissue has a 1 year low of C$7.99 and a 1 year high of C$9.72. The firm's 50 day moving average is C$8.33 and its two-hundred day moving average is C$8.38.
KP Tissue Dividend Announcement
The company also recently declared a quarterly dividend, which was paid on Tuesday, October 15th. Shareholders of record on Tuesday, October 15th were given a dividend of $0.18 per share. This represents a $0.72 annualized dividend and a dividend yield of 8.71%. The ex-dividend date was Friday, September 27th. KP Tissue's payout ratio is 120.00%.
KP Tissue Company Profile
(
Get Free Report)
KP Tissue Inc, through its interest in Kruger Products L.P., produces, distributes, markets, and sells a range of disposable tissue products in Canada and the United States. The company operates through two segments, Consumer and Away-From-Home. It offers bathroom and facial tissues, paper towels, and napkins.
Featured Stories
Before you consider KP Tissue, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and KP Tissue wasn't on the list.
While KP Tissue currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.